Oxidized Cholesterol Metabolites Found in Human Atherosclerotic Lesions Promote Apolipoprotein C-II Amyloid Fibril Formation

Cameron R. Stewart,§ Leanne M. Wilson,§ Qinghai Zhang, Chi L. L. Pham,§ Lynne J. Waddington, Maree K. Staples,§ David Stapleton,§ Jeffery W. Kelly, and Geoffrey J. Howlett*§
Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia, Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, and Commonwealth Scientific and Industrial Research Organisation, Parkville, Victoria 3052, Australia
Biochemistry, 2007, 46 (18), pp 5552–5561
DOI: 10.1021/bi602554z
Publication Date (Web): April 13, 2007
Copyright © 2007 American Chemical Society

 This work was supported by Australian Research Council Grant DP0449510 and National Health and Medical Research Council Grant 208913 to G.J.H. and by NIH Grant NS 50636 to J.W.K.

,

 These authors contributed equally.

,
§

 The University of Melbourne.

,

 The Scripps Research Institute.

,

 Commonwealth Scientific and Industrial Research Organisation.

,
*

 Corresponding author. Phone:  61 3 8344 2271. Fax:  61 3 9347 7730. E-mail:  ghowlett@unimelb.edu.au.

Abstract

Abstract Image

Apolipoprotein amyloid deposits and lipid oxidation products are colocalized in human atherosclerotic tissue. In this study we show that the primary ozonolysis product of cholesterol, 3β-hydroxy-5-oxo-5,6-secocholestan-6-al (KA), rapidly promotes human apolipoprotein (apo) C-II amyloid fibril formation in vitro. Previous studies show that hydrophobic aldehydes, including KA, modify proteins by the formation of a Schiff base with the lysine ε-amino group or N-terminal amino group. High-performance liquid chromatography, mass spectrometry, and proteolysis of KA-modified apoC-II revealed that KA randomly modified six different lysine residues, with primarily one KA attached per apoC-II molecule. Competition experiments showed that an aldehyde scavenging compound partially inhibited the ability of KA to hasten apoC-II fibril formation. Conversely, the acid derivative of KA, lacking the ability to form a Schiff base, accelerated apoC-II fibril formation, albeit to a lesser extent, suggesting that amyloidogenesis triggered by KA involves both covalent and noncovalent mechanisms. The viability of a noncovalent mechanism mediated by KA has been observed previously with α-synuclein aggregation, implicated in Parkinson's disease. Electron microscopy demonstrated that fibrils formed in the presence of KA had a similar morphology to native fibrils; however, the isolated KA−apoC-II covalent adducts in the absence of unmodified apoC-II formed fibrillar structures with altered ropelike morphologies. KA-mediated fibril formation by apoC-II was inhibited by the addition of the amine-containing compound hydralazine and the lipid-binding protein apoA-I. These in vitro studies suggest that the oxidized small molecule pool could trigger or hasten the aggregation of apoC-II to form amyloid deposits.

Tools

History

  • Published In Issue May 08, 2007
  • Received December 12, 2006
    Revised Manuscript Received March 9, 2007

Recommend & Share